Back to discover
Disease

Soft tissue sarcoma

Late-stage therapeutic development
Also known as connective tissue sarcoma, malignant mesenchymal tumor, malignant mesenchymal tumour, non-Rhabdo. soft tissue sarcoma+5 more

connective tissue sarcoma, malignant mesenchymal tumor, malignant mesenchymal tumour, non-Rhabdo. soft tissue sarcoma, sarcoma of soft tissue, sarcoma of the soft tissue, soft part sarcoma, malignant soft tissue tumor, malignant soft tissue tumour.

19
Clinical trials
9
Associated genes
2
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 3 clinical trials expected to report results, the earliest in Q3 2028.
Upcoming Milestones
Clinical Milestones7View
Results posted 1
Results expected 3
Recently completed 1
Other updates 2
Activity timeline7

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Trabectedinapproved

Approval — Trabectedin Accord is indicated for the treatment of adult patients with advanced soft ti… (2025)

Pazopanibapproved

Approval — Renal-cell carcinoma (RCC) Votrient is indicated in adults for the first-line treatment o… (2010)

Tasonerminapproved

Approval — Beromun is indicated in adults as an adjunct to surgery for subsequent removal of the tum… (1999)

Clinical trials

17 sponsors · 1 new · 2 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
19
All trials
6
Active
11
Late-stage
6
Completed
Late-stage studies

Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma

Phase 3 · Recruiting · Institut Claudius Regaud

A Prospective, Open-Label, Single-Arm Clinical Study of Anlotinib Combined With Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Phase 4 · Recruiting · Guangdong Provincial People's Hospital

Phase III Study Comparing Trabectedin (T) Versus T Plus tTF-NGR to Entrap T Inside the Tumor in Patients With Metastatic and/or Refractory Soft Tissue Sarcoma (STS)

Phase 3 · Recruiting · Universität Münster

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)

Phase 2/3 · Completed · National Cancer Institute (NCI)

Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age

Phase 3 · Completed · Children's Oncology Group

Molecular Profiling of Advanced Soft-tissue Sarcomas. A Phase III Study

Phase 3 · Completed · Institut National de la Santé Et de la Recherche Médicale, France
Recruiting

Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma

Phase 3 · Recruiting · Institut Claudius Regaud

A Non-Randomized, Open-label Phase II Trial Testing the Activity of XL092 (Zanzalintinib) in Patients With Advanced Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma

Phase 2 · Recruiting · Northwestern University

A Prospective, Open-Label, Single-Arm Clinical Study of Anlotinib Combined With Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Phase 4 · Recruiting · Guangdong Provincial People's Hospital

A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers: Head&Neck (H&N), Neuroendocrine Tumors (NET) and Soft Tissue Sarcoma (STS).

Phase 2 · Recruiting · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Maintenance Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)

Phase 2 · Recruiting · National Health Research Institutes, Taiwan

Phase III Study Comparing Trabectedin (T) Versus T Plus tTF-NGR to Entrap T Inside the Tumor in Patients With Metastatic and/or Refractory Soft Tissue Sarcoma (STS)

Phase 3 · Recruiting · Universität Münster
Recently completed

Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

Phase 2 · Completed · Italian Sarcoma Group

Molecular Profiling of Advanced Soft-tissue Sarcomas. A Phase III Study

Phase 3 · Completed · Institut National de la Santé Et de la Recherche Médicale, France

A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults

Phase 3 · Completed · University Hospital Tuebingen

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)

Phase 2/3 · Completed · National Cancer Institute (NCI)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Phase 3 · Completed · Eli Lilly and Company

Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age

Phase 3 · Completed · Children's Oncology Group

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2025emaApproval — Trabectedin· Trabectedin Accord is indicated for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients. Trabectedin Accord in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. source ↗
2010emaApproval — Pazopanib· Renal-cell carcinoma (RCC) Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Soft-tissue sarcoma (STS) Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Efficacy and safety have only been established in certain STS histological tumour subtypes. source ↗
2007emaApproval — Trabectedin· Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients. Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. source ↗
1999emaApproval — Tasonermin· Beromun is indicated in adults as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft-tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated-limb perfusion (ILP). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

9 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

PDGFRA0.61CSF1R0.51LCK0.51ITK0.46RABEP10.18ZNF4790.18MAGEA40.08GID40.04RTL90.01

Disease biology

2 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Platelet-derived growth factor receptor alphavia PDGFRA0.61Macrophage colony-stimulating factor 1 receptorvia CSF1R0.51

Reference

Authoritative identity, definition & identifiers.

Synonyms

connective tissue sarcoma, malignant mesenchymal tumor, malignant mesenchymal tumour, non-Rhabdo. soft tissue sarcoma, sarcoma of soft tissue, sarcoma of the soft tissue, soft part sarcoma, malignant soft tissue tumor, malignant soft tissue tumour

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.